BGBIO Share Price Performance
NOK 1.17
-7.27 (-86.14%)
Price NOK 1.17
Share Pricen/a
BerGenBio ASA Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
BGBIO Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
BerGenBio ASA Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 19, 2025
- -2.75
- 100.00%
- -1,990.45%
- 0%
About BGBIO
- Founded
- 2007
- Employees
- 7
- CEO
- WebsiteView website
As of October 29, 2025, BerGenBio ASA was acquired by Oncoinvent ASA, in a reverse merger transaction. BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway.
